The groundbreaking success of the copyright undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Although early returns were significant, the end of patents and the rise of cheaper alternatives have diminished market share. Consequently, a thorough evaluation of